A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: LAMA; Drug: Tiotropium + Olodaterol; Drug: Other LABA/LAMA

Study type: Observational

Funder types: Industry

Identifiers

NCT04011475

1237-0086

Details and patient eligibility

About

Study to collect the data on Chronic Obstructive Pulmonary Disease (COPD) patients who were administered with Long-Acting Beta-Agonist/ Long-Acting Muscarinic Antagonist (LABA/LAMA) (Fixed-dose Combination (FDC) or free combo) or LAMA treatment

Enrollment: 1,617 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients who fulfil ALL the following criteria are included.

1. Patients who diagnosed with COPD who were prescribed with LABA/LABA (FDC or free combo) as a new initiation or switching from other therapy (i.e., single/dual/triple), or newly receiving LAMA treatment for 3 months at least prior to 30 June 2018
2. Male or female patients ≥ 40 years of age

Exclusion criteria

1. Patients who meet the following criterion are not included.

• Patients with documented diagnosis of bronchial asthma, asthma-COPD overlap syndrome (ACOS), bronchiectasis, cystic fibrosis, or lung cancer

Trial design

1,617 participants in 3 patient groups

Subjects with Tiotropium and Olodaterol

Treatment:

Drug: Tiotropium + Olodaterol

Subjects treated with other LABA/LAMA therapy

Treatment:

Drug: Other LABA/LAMA

Subjects treated with LAMA therapy

Treatment:

Drug: LAMA